Extraordinary General Meeting in Vigmed Holding AB (publ) resolves on a new share issue of approximately MSEK 57

On 12 November 2015, Vigmed Holding AB (publ) held an Extraordinary General Meeting. At the EGM, 21,155,456 shares were represented corresponding to 48 % of the total number of shares and votes in the company. The EGM resolved, in accordance with the Board of Directors’ proposal, on a new share issue of not more than 21,916,666 shares resulting in an increase of the share capital by not more than approximately SEK 442,330.06. The company’s shareholders shall have preferential right to subscribe for new shares in relation to their previous shareholdings whereby two (2) shares shall entitle to subscription of one (1) new share. The subscription price shall be SEK 2.60 per new share which means that the rights issue, at full subscription, will provide the company with proceeds of approximately MSEK 57 before rights issue costs.

The record date for entitlement to participate in the rights issue with pre-emptive right is 19 November 2015. Subscription for new shares by exercise of subscription rights shall be made by simultaneous cash payment during the period as from 23 November 2015 up to and including 7 December 2015.

Helsingborg, November 12, 2015

Vigmed Holding AB (publ)

For further information contact:

Chairman of the board, Lennart Holm +46 70 630 8562 or CEO, Henrik Olsen +46 76 349 7364

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 500 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor

Tags:

About Us

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and the company has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information can be found on Vigmed’s home page: www.vigmed.com

Subscribe

Documents & Links